VNP40101M in Treating Patients With Advanced or Metastatic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed advanced or metastatic solid tumor or lymphoma for which no curative or standard effective therapy exists
• Measurable or evaluable disease
• Primary brain tumors or brain metastases allowed provided neurologic deficits are stable and do not preclude study compliance
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-1
• Life expectancy
• At least 3 months
• Hematopoietic
• Granulocyte count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hematocrit at least 30% (transfusion allowed)
• No bleeding diathesis
• Hepatic
• PT and PTT no greater than 1.5 times the upper limit of normal (ULN)
• Bilirubin no greater than 1.5 times ULN
• ALT and AST no greater than 1.5 times ULN (3 times ULN if liver metastases present)
• Albumin at least 2.5 gm/dL
• Renal
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular
• At least 3 months since prior myocardial infarction
• No symptomatic coronary artery disease
• No arrhythmias requiring medication
• No uncontrolled congestive heart failure
• Pulmonary
• No dyspnea on minimal or moderate exertion
• DLCO and FEV1 at least 60% predicted
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No uncontrolled active bleeding (e.g., active peptic ulcer disease)
• No active infection
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Recovered from acute toxicities of prior biologic therapy (persisting, chronic toxicity allowed if stable and no greater than grade 1)
• Chemotherapy
• More than 6 months since prior high-dose chemotherapy with stem cell support
• More than 3 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas)
• Recovered from acute toxicities of prior chemotherapy (persisting, chronic toxicity allowed if stable and no greater than grade 1)
• Endocrine therapy
• At least 2 weeks since prior hormonal therapy
• Radiotherapy
• Recovered from acute toxicities of prior radiotherapy (persisting, chronic toxicity allowed if stable and no greater than grade 1)
• Surgery
• At least 2 weeks since prior surgery
• Other
• No other concurrent standard or investigational treatment for cancer
• No concurrent disulfiram